{"title":"交叉免疫原性:在使用Remicade治疗的炎症性肠病患者中,英夫利昔单抗抗体识别的生物类似物Remsima相似","authors":"J.R. Márquez Velásquez","doi":"10.1016/j.eii.2015.12.002","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"15 1","pages":"Pages 19-21"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.12.002","citationCount":"1","resultStr":"{\"title\":\"Inmunogenicidad cruzada: anticuerpos para infliximab en pacientes con enfermedad inflamatoria intestinal tratados con Remicade reconocen similarmente al biosimilar Remsima\",\"authors\":\"J.R. Márquez Velásquez\",\"doi\":\"10.1016/j.eii.2015.12.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":100473,\"journal\":{\"name\":\"Enfermedad Inflamatoria Intestinal al Día\",\"volume\":\"15 1\",\"pages\":\"Pages 19-21\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.eii.2015.12.002\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Enfermedad Inflamatoria Intestinal al Día\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1696780115001104\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedad Inflamatoria Intestinal al Día","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1696780115001104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Inmunogenicidad cruzada: anticuerpos para infliximab en pacientes con enfermedad inflamatoria intestinal tratados con Remicade reconocen similarmente al biosimilar Remsima